In­cyte CEO Hervé Hop­penot sees block­buster po­ten­tial for Opzelu­ra, even as an­a­lysts shake their heads in doubt

De­spite In­cyte’s top­i­cal atopic der­mati­tis drug get­ting slapped with a black box warn­ing — and com­ing in be­low Wall Street’s ex­pec­ta­tions for its first quar­ter on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER